Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
BPC-157, written BPC 157 in most of the primary literature, is a synthetic pentadecapeptide that has been studied in tendon and ligament models for more than two decades. Tendons and ligaments are dense connective tissues with low cellularity and a sparse blood supply, which is why they repair slowly in experimental injury models and have become a proving ground for peptides investigated for angiogenic, cell-migration, and cytoprotective signaling. Research on bpc 157 in these tissues spans fibroblast cultures, tendon explants, and rodent models of Achilles transection, tendon-to-bone detachment, and medial collateral ligament transection.
A 2025 systematic review of the orthopaedic sports-medicine literature brought this body of work together and concluded that the evidence is almost entirely preclinical. This article summarizes what the tendon and ligament studies measured, which signaling pathways they implicate, and where the review located the gaps. All material describes laboratory findings in cells and animals; the compound is supplied for research use only, not for human consumption.
BPC 157 Identity and Why Tendon Models Use It
Molecular Profile
BPC-157 is a fifteen-residue fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) of a larger protective protein identified in gastric juice. Its stability in acidic conditions made it convenient for early gastrointestinal research, and its reported influence on blood-vessel formation later drew connective-tissue researchers to it. The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported Value |
|---|---|
| Class | Synthetic pentadecapeptide, gastric protein fragment |
| Sequence length | 15 amino acids |
| Molecular formula | C62H98N16O22 |
| Approximate molecular weight | 1419.5 g/mol |
| Literature designations | BPC 157, PL 14736, PL-10, Bepecin |
| Pathways studied in connective tissue | VEGFR2-Akt-eNOS, nitric oxide, FAK-paxillin, EGR1, growth hormone receptor |
The Connective-Tissue Problem
Tendon and ligament repair in animal models passes through an inflammatory phase, a proliferative phase dominated by fibroblast migration and type III collagen deposition, and a long remodeling phase in which collagen matures toward the aligned, type I-rich structure of native tissue. Because these tissues are hypovascular and hypocellular, both the arrival of reparative cells and the supply of oxygen limit the process. A peptide investigated for angiogenesis and fibroblast migration therefore addresses both bottlenecks, which explains why BPC-157 appears so often in this literature.
Tendon Fibroblast Culture and Explant Studies
Outgrowth From Achilles Tendon Explants
The most detailed cellular work comes from Chang and colleagues in the Journal of Applied Physiology in 2011. Using explants of rat Achilles tendon, they reported that BPC 157 increased the outgrowth of tendon fibroblasts from the tissue, an assay that models the first step of repair, in which resident cells leave the tendon body and populate a defect. The peptide did not markedly change fibroblast proliferation in isolation, but it increased cell survival when cultures were exposed to hydrogen peroxide and increased migration in transwell assays.
The FAK-Paxillin Adhesion Pathway
Mechanistically, the 2011 study linked these effects to phosphorylation of focal adhesion kinase (FAK) and its binding partner paxillin, two proteins that assemble the adhesion complexes a migrating cell uses to pull itself forward. That observation gave the migration findings a molecular explanation and is why the pathway appears in nearly every mechanistic summary of the peptide.
Growth Hormone Receptor Expression
In a 2014 follow-up in Molecules, the same group reported that BPC 157 increased expression of the growth hormone receptor in cultured tendon fibroblasts at both the mRNA and protein level. Because growth hormone signaling through JAK2 is associated with collagen synthesis, the finding suggested a route by which the peptide might amplify an endogenous anabolic signal in tendon cells rather than acting as a growth factor itself. These culture studies are often compared with those on thymosin beta-4 fragments such as TB-500, which are investigated for actin-dependent migration.
Rodent Tendon Models
Achilles Tendon Transection
The foundational in-vivo study, from Staresinic and colleagues in 2003, used complete transection of the rat Achilles tendon. Investigators followed biomechanical endpoints such as load to failure and Young’s modulus, a walking-track Achilles functional index, and histology of the repair callus. Tendons from BPC 157 groups were reported to show higher failure loads, better fiber organization, and an earlier shift from inflammatory to reparative cell populations than controls.
Tendon-to-Bone Detachment
Krivic and colleagues extended the model in 2006 to detachment of the Achilles tendon from the calcaneus, a design that tests the enthesis, the fibrocartilage transition between tendon and bone that is notoriously slow to reform. Their reports described improved tendon-to-bone reattachment that persisted in animals given a corticosteroid known to impair connective-tissue repair. Later work from the same Zagreb group applied the peptide to disabled myotendinous junctions in rats, and other groups have examined rotator cuff tear models.
Ligament Models
Ligaments join bone to bone, experience multidirectional loading, and rely even more heavily on collagen alignment than tendons. The principal ligament study, by Cerovecki and colleagues in the Journal of Orthopaedic Research in 2010, used transection of the rat medial collateral ligament (MCL). The design tracked biomechanical strength, knee stability and gait, and histology at several timepoints. Ligaments from the BPC 157 groups were reported to be stronger and better organized than controls at matched intervals. The study matters because it showed the tendon findings translate to a second dense connective tissue with a different mechanical role, and because MCL transection is a standardized model other laboratories can reproduce. Researchers extending this work often study BPC-157 alongside TB-500 in the same models, and a combined BPC-157 and TB-500 preparation exists for that purpose.
The 2025 Systematic Review and the State of the Evidence
Vasireddi and colleagues published a systematic review of BPC 157 in orthopaedic sports medicine in 2025. After screening more than 500 abstracts, they included roughly three dozen studies from the early 1990s onward, nearly all preclinical, grouped into tendon and ligament, muscle, bone, and general mechanism categories; tendon and ligament models formed the largest tissue-specific group. The review characterized the peptide’s activity as pleiotropic, citing VEGF, FAK-paxillin, nitric oxide synthase, KRAS, and MAPK signaling, and noted that outcomes across models were consistent in direction. The table below summarizes the principal models; these values reflect commonly reported laboratory attributes and are provided for comparison only.
| Model | Tissue | Typical endpoints | Reported pattern |
|---|---|---|---|
| Achilles tendon explant culture | Tendon fibroblasts | Outgrowth, migration, survival under H2O2, FAK-paxillin | Increased outgrowth, migration, survival |
| Achilles tendon transection (rat) | Tendon | Load to failure, Young’s modulus, functional index, histology | Higher failure load, better fiber organization |
| Achilles detachment from calcaneus (rat) | Enthesis | Reattachment strength, histology, corticosteroid challenge | Improved tendon-to-bone reattachment |
| Medial collateral ligament transection (rat) | Ligament | Biomechanics, knee stability, gait, histology | Stronger, better organized ligament |
| Myotendinous junction and rotator cuff (rat) | Muscle-tendon, shoulder | Function, biomechanics, histology | Improved repair |
The review also identified the limits of this literature: much of it originates from a few research groups, the models are almost exclusively rodent, and reporting of peptide identity and purity is inconsistent. For laboratories extending the work, that last point argues for sourcing material with lot-specific documentation; the guide to reading a peptide COA explains which lines to check. The broader context of how BPC-157 compares with other connective-tissue peptides is covered in the recovery and tissue-repair peptide overview.
Where Tendon and Ligament Research Goes Next
Three directions stand out. First, independent replication of the Achilles and MCL models outside the original groups would strengthen the evidence base. Second, larger-animal models would test whether the rodent findings scale. Third, the mechanistic threads, FAK-paxillin, VEGFR2, growth hormone receptor expression, and EGR1, have mostly been studied separately, and experiments connecting them within a single tendon model would clarify which pathway carries the effect. Until then, bpc 157 remains one of the most thoroughly characterized peptides in preclinical tendon and ligament research. It and related compounds are listed in the research peptide catalog.
Frequently Asked Questions
What is BPC 157 studied for in tendon research?
In tendon models BPC 157 is investigated for fibroblast outgrowth and migration, cell survival under oxidative stress, angiogenic signaling through VEGFR2, and biomechanical recovery after Achilles tendon transection or detachment in rats. All are preclinical endpoints.
Which signaling pathways link BPC 157 to tendon cells?
Culture studies report increased phosphorylation of focal adhesion kinase and paxillin, which drive cell migration, and increased growth hormone receptor expression in tendon fibroblasts. In-vivo work adds VEGFR2-Akt-eNOS activation and nitric oxide involvement.
Has BPC 157 been studied in ligament models?
Yes. The principal study used medial collateral ligament transection in rats and reported stronger, better organized ligaments on biomechanical and histological measures than controls, extending the tendon findings to a second connective tissue.
What did the 2025 systematic review of BPC 157 conclude?
The review included roughly three dozen studies, nearly all preclinical, and found consistent directional effects across tendon, ligament, muscle, and bone models, while noting that the literature comes from few research groups, relies on rodents, and reports peptide identity inconsistently.
What is the molecular weight and sequence of BPC 157?
BPC 157 is a fifteen-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22, and an approximate molecular weight of 1419.5 g/mol.
Is BPC 157 intended for human use?
No. BPC 157 is a laboratory research compound. It is supplied for research use only and is not intended for human consumption, self-administration, or therapeutic use.
References and Further Reading
- Vasireddi and colleagues, 2025, systematic review of BPC 157 in orthopaedic sports-medicine research. PubMed: BPC-157 orthopaedic sports medicine systematic review
- Chang and colleagues, 2011, on tendon fibroblast outgrowth and FAK-paxillin phosphorylation. PubMed: BPC 157 tendon fibroblast outgrowth FAK paxillin
- Chang and colleagues, 2014, on growth hormone receptor expression in tendon fibroblasts. PubMed: BPC 157 growth hormone receptor tendon fibroblasts
- Staresinic and colleagues, 2003, on rat Achilles tendon transection. PubMed: BPC 157 Achilles tendon transection rat
- Krivic and colleagues, 2006, on Achilles tendon-to-bone reattachment. PubMed: BPC 157 tendon to bone healing
- Cerovecki and colleagues, 2010, on medial collateral ligament transection in rats. PubMed: BPC 157 ligament healing rat
- Hsieh and colleagues, 2017, on VEGFR2 activation and BPC 157 angiogenic activity. PubMed: BPC157 VEGFR2 activation
